SSelectStock

AHCLAnlon Healthcare Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)

Anlon Healthcare Limited manufactures and sells advance pharmaceutical intermediates in India and internationally. The company offers active pharmaceutical ingredients (API); nutraceutical API products; personal care ingredients; and veterinary API products. Its products are used in anti-inflammatory (NSAID), analgesic, antipyretic, antihistamine, antidepressant, antipsychotic, anticoagulant, antihypertensive, nutrition, anti-arrhythmic, anti-hyper parathyroid, antiplatelet, ant diabetic, gastroesophageal reflux disease (GERD), and anti-rheumatic therapeutics areas. The company was incorporated in 2013 and is based in Rajkot, India.

₹24.70
▼ 3.36%
58Decent

Mkt Cap
₹1,313 Cr
P/E
36.3
P/B
4.9
Div Yield
0.00%
52W High
₹37.24
52W Low
₹10.37

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)1,312.90
P/E36.32
P/B4.85
PEG0.94
ROE %12.40
ROCE %16.80
Debt / Equity0.17
EPS0.68
Revenue Growth %163.00
Profit Growth %38.90
Dividend Yield %0.00
Promoter Holding %73.27
FII Holding %0.00
DII Holding %—
Beta0.47

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

None of the 16 pattern scanners currently detects a setup on AHCL — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.

HOLDConviction 62%

The picture

  • • Revenue growth: 163.0% YoY
  • • Profit growth: 38.9% YoY
  • • ROCE: 16.8%
  • • Price vs SMA50: above
  • • Price vs SMA200: above
  • • Golden cross setup: SMA50 above SMA200

Bull case

  • • Revenue growth: 163.0% YoY
  • • Profit growth: 38.9% YoY
  • • ROCE: 16.8%
  • • Price vs SMA50: above

Bear case

  • • Dividend yield: 0.00%
  • • MACD: bearish
  • • Price vs EMA21: below
  • • 1-month return: -16.8%

Key risks

  • • Dividend yield: 0.00%
  • • MACD: bearish

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹24.70
Stop Loss
₹22.91
risk 7.3%
Target 1 (1.5R)
₹27.39
+10.9%
Target 2 (3R)
₹30.07
+21.7%
Support (20d)
₹23.14
Resistance (52w)
₹37.24
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹1.79/share
ATR (volatility)
₹1.88
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹1.88). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental81
Technical46
Momentum50
Risk (safety)47

Peers — Pharma

SHUKRAPHAR▲ 4.65%
73
LAURUSLABS▲ 4.51%
70
JBCHEPHARM 0.00%
70
ZYDUSLIFE▲ 2.74%
68
IPCALAB▼ 0.75%
66
CORONA▼ 0.47%
65